Insights & news

European Commission Started Consultations on Revision of Variation Framework for Medicines for Human Use

  • 01/09/2023
  • News

On 29 August 2023, the European Commission (the Commission) started public consultations on a revision of the variation framework for medicines for human use. This set of rules governs changes to an existing marketing authorisation for medicines. The Commission is probing for ways to achieve efficiency gains in hopes of reducing the administrative burden for both marketing authorisation holders and the regulatory authorities. Stakeholders will welcome efficiencies in the face of the large number of variations.
 
While the Pharmaceutical Package (seeVan Bael & Bellis Life Sciences News and Insights, 3 May 2023), once adopted, will bring about further improvements for managing post-authorisation changes, the Commission points out that it will still take “some years” for this set of rules to take effect. This makes a short-term approach necessary and will involve amendments to delegated Commission Regulation 1234/2008 which governs variations to the terms of marketing authorisations of medicines for both human and veterinary use, regardless of whether they are centrally authorised or form the subject of a national authorisation.
 
The Commission is considering re-classifying specific variations into lower categories; adding flexibility regarding the level of technical information that must be provided; clarifying the changes and data that must be communicated to the regulators; simplifying the single submission or notification of variations (“grouping”); and creating work-sharing procedures.   

Key contacts

Related insights

Sign up for updates
    • 17/06/2024
    • News

    Publication of Regulation Revising Variations Framework for Medicines for Human Use

    Today, on 17 June 2024, the Official Journal of the European Union publishes Commission Delegated Regulation (EU) 2024/1701 of 11 March 2024 “amending Regulation (EC) No 1234/2008 as regards the examination of variations to the terms of marketing authorisations for medicinal products for human use”

    Read more
    • 13/06/2024
    • News

    Luxembourg Competition Authority Carries Out Dawn Raids in Life Sciences Industry

    The Luxembourg Competition Authority (LCA) announced today that it carried out on-premise inspections in the life sciences sector targeting suppliers of pharmaceutical and related products (see, attached press release). In keeping with good operating practices, the LCA did not identify the firms which it visited. Likewise, it was not forthcoming with details regarding the practices which it sought to review and only referred to “anticompetitive arrangements”.

    Read more
    • 13/06/2024
    • News

    European Commission Pursues Alleged Member of Pharmaceuticals Cartel Following Settlement with Other Cartel Members

    Today, the European Commission (the Commission) publicly announced that it sent a Statement of Objections to Alchem for that firm’s alleged involvement in a cartel in relation to N-Butylbromide Scopolamine/Hyoscine (SNBB), the active ingredient of the anti-cramp medicine Buscopan® and its generic versions. Earlier, the Commission had concluded a settlement agreement with the other members of the cartel which agreed to the payment of a total fine of EUR 13.4 million

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *